例如:"lncRNA", "apoptosis", "WRKY"

Plasma prolidase levels as a biomarker for polycystic ovary syndrome.

Biomark Med. 2018 Jun;12(6):597-606. doi:10.2217/bmm-2017-0306. Epub 2018 Jun 06
Richa Bhatnager 1 , Smiti Nanda 2 , Amita S Dang 1
Richa Bhatnager 1 , Smiti Nanda 2 , Amita S Dang 1

[No authors listed]

Author information
  • 1 Centre for Medical Biotechnology, Maharshi Dayanand University, Rohtak 124001, India.
  • 2 Department of Obstetrics and Gynecology, Pandit Bhagwat Dayal Sharma Institute of Medical Sciences, Rohtak 124001, India.

摘要


AIM:Assessment of plasma prolidase levels in polycystic ovary syndrome (PCOS). PATIENTS & METHODS:PCOS patients were screened according to Rotterdam Criterion and prolidase levels were measured. RESULTS:A total of 170 patients and 160 controls were recruited for the study and it was found that prolidase levels were significantly higher in PCOS group (991.10 ± 39.52) than control (621.89 ± 23.94). Furthermore it has been found that prolidase levels increase with the number of cysts in ovaries. CONCLUSION:Significant difference between prolidase levels in PCOS and control shows that it may be used as a diagnostic marker for disease. In addition to this, there is a positive correlation found between prolidase levels and number of cysts, hence may be used as a prognostic marker to monitor disease status.

KEYWORDS: PCOS, ROC curve, collagen, diagnostic marker, extracellular matrix, polycystic ovaries, prognostic marker, prolidase, transvaginal ultrasonography